Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maine for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maine only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maine (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Anthony Ekong (NPI 1336171875)

Field	Value
Entity Type	Individual
Organization	Anthony Ekong
Address	336 Mount Hope Ave Ste 1
City	Bangor
State	ME
ZIP	04401
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	July 7, 2006

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

This provider’s billing profile is effectively single‑payer: total Medicare revenue is $1.1M and there is no Medicaid billing on file. The absence of Medicaid activity indicates the practice’s revenue and utilization patterns are driven solely by Medicare in the available data, which raises exposure to Medicare policy and market dynamics rather than state Medicaid contracting shifts.

Revenue is highly concentrated in intravitreal biologic therapies: the precomputed top-3 Medicare codes account for 67.2% of this provider’s total Medicare revenue, driven by J2777 (27.7% of Medicare revenue), J0178 (21.1%), and Q5124 (18.3%). This concentration means a small set of drug codes dominates the practice’s income base and changes to utilization or reimbursement for those agents would materially affect total revenue.

The code mix and descriptions point to a retina-centered, injection-based ophthalmology practice: high revenue from J2777, J0178, and Q5124 are anti-VEGF/faricimab/ranibizumab products used for retinal disease, while 67028 (11.3% of Medicare revenue) captures isolated intravitreal injections. Imaging and diagnostic retinal codes such as 92134 also appear in the top codes, consistent with a specialty retina clinic that pairs frequent injections with diagnostic imaging.

Competitive standing across top drug codes is mixed. J2777 (J2777 – Injection, faricimab-svoa) accounts for $302.8K (27.7%) and ranks #985 of 2039 (51th percentile; typical, unremarkable volume), indicating ordinary national participation in faricimab use; J0178 (aflibercept) generates $230.8K (21.1%) but ranks #2242 of 3204 (30th percentile; typical, unremarkable volume), suggesting relatively lower aflibercept volume versus peers; by contrast Q5124 (biosimilar ranibizumab) is $200.2K (18.3%) and ranks #28 of 122 (78th percentile; typical, unremarkable volume), reflecting comparatively strong adoption of the biosimilar within its smaller national cohort.

Procedural and imaging volumes show pockets of above‑typical activity: 92134 (retinal imaging/OCT) appears as 1.7K claims for $48.8K (4.5% of Medicare revenue) and ranks #1280 of 26868 (95th percentile; notably above typical national volume), indicating a high OCT/imaging workload relative to national peers. 67028 (intravitreal injection as an isolated procedure) also posts 1.6K claims for $123K (11.3%) and ranks #739 of 4255 (83th percentile; typical, unremarkable volume), consistent with a high-throughput injection practice supported by imaging.

Although bevacizumab (J9035) contributes a smaller share of revenue ($40.7K, 3.7% of Medicare revenue), its rank (#129 of 1852, 93th percentile; typical, unremarkable volume) shows the provider is a high-volume user of lower-cost compounded or off-label therapy. This mix—high volume of low-cost bevacizumab plus substantial revenue from higher‑priced branded or biosimilar agents—suggests the practice balances cost-tiered therapeutics in retinal care.

Practice tenure is long-established: the NPI was enumerated on 2006-07-07 (~20 years ago). That length of enrollment is consistent with a stable, experienced retinal specialist whose referral patterns and patient base are likely mature, which aligns with the sustained imaging and injection volumes reported.

Operational and reimbursement sensitivity is elevated because a large share of revenue is tied to a few injectable drugs and associated procedures. Given that top drug codes and injections make up the majority of Medicare revenue and there is no Medicaid revenue diversification, any shifts in Medicare drug reimbursement, biosimilar uptake, or clinical guidelines affecting injection frequency could have outsized financial impact on this provider.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

12 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2777	Injection, faricimab‑svoa, 0.1 mg	10,440	$30	$302.8K
J0178	Injection, aflibercept, 1 mg	330	$690	$230.8K
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	1,170	$170	$200.2K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	1,560	$80	$123K
J2778	Injection, ranibizumab, 0.1 mg	290	$180	$50K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	1,740	$30	$48.8K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	490	$80	$41.3K
J9035	Injection, bevacizumab, 10 mg	770	$50	$40.7K
92012	For this CPT code, an Ophthalmologist sees an established patient for an intermediate level eye examination. Generally, a patient is considered to be "established" if the same physician, or any…	480	$60	$29.4K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	90	$110	$10.3K

Showing 1–10 of 12

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 12 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maine Distribution

Anthony Ekong — 6 of 12 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maine

Full comparison — all codes billed, vs. state median

12 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	13	20	990	$690	$652.2K
J2777	5	10	9,840	$30	$407.6K
J2778	7	10	690	$180	$155.6K
Q5124	1	10	670	$170	$112.5K
67028	1	30	410	$90	$51.1K
92014	16	240	150	$80	$14.7K
J9035	1	10	60	$50	$8.5K
92235	8	10	50	$90	$7.5K
92012	2	130	50	$60	$5.2K
92134	2	180	50	$30	$4.5K

Showing 1–10 of 12

Related Providers

Other providers that share a Tax Identification Number (TIN) with Anthony Ekong, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Retina & Uveitis Consultants Of Maine	ME	Retina Specialist (Ophthalmology) Physician	$0	$385.3K

Nearby Providers

Other providers in the same ZIP code as Anthony Ekong, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Eastern Maine Medical Center	ME	General Acute Care Hospital	$0	$159.3M
Creative Options, LLC	ME	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$78.7M
Mas Medical Staffing Corporation	ME	Community/Behavioral Health Agency	$0	$62.5M
Ohi	ME	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$61.9M
Ohi	ME	Mental Illness Community Based Residential Treatment Facility	$0	$39.6M
St. Joseph Hospital	ME	General Acute Care Hospital	$0	$38.8M
Mert Enterprises, Inc.	ME	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$36.3M
Penobscot Community Health Center	ME	Federally Qualified Health Center (FQHC)	$0	$27.3M
Amicus	ME	Developmentally Disabled Services Day Training Agency	$0	$26.1M
Branches, LLC	ME	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$25.4M

Anthony Ekong — Billing Profile & Reimbursement Data

Sign up for Anthony Ekong — Billing Profile & Reimbursement Data policy alerts

Anthony Ekong — Billing Profile & Reimbursement Data

Sign up for Anthony Ekong — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References